论文部分内容阅读
Objective: This study was aimed to explore the expression of microRNA-32(miR-32) in multiple myeloma(MM), and study its association with β2-microglobulin and staging of MM by Durie-Salmon classification. Methods: The expression level of miR-32 in bone marrow mono-nuclear cells of MM were examined by real-time polymerase chain reaction(real-time PCR), and the correlations between the expression level of miR-32 and related clinic pathologic features β2-microglobulin, staging of MM by Durie-Salmon classification were further analyzed. Results: The expression of miR-32 in MM patients was obviously higher than that in normal control(P < 0.05). The expression of miR-32 in relapsed/ refractory MM patients was obviously higher than that in newly diagnosed MM patients. The expression of miR-32 in MM patients decreased after chemical therapy than that before treatment, especially in effective group(P < 0.05). There was no statistically significant change in ineffective/progress group after chemical therapy(P > 0.05).The expression of miR-32 was associated to staging of MM and β2-microglobulin level. Conclusion: Expression level of miR-32 in MM patients is significantly higher than that in normal bone marrow, these data indicated that miR-32 may play an important role in the development of MM. High-regulated expression of miR-32 was associated with β2-microglobulin and staging of MM by Durie-Salmon classification.
Objective: This study was aimed to explore the expression of microRNA-32 (miR-32) in multiple myeloma (MM), and study its association with β2-microglobulin and staging of MM by Durie-Salmon classification. Methods: The expression level of miR-32 in bone marrow mono-nuclear cells of MM were examined by real-time polymerase chain reaction (real-time PCR), and the correlations between the expression level of miR-32 and related clinic pathologic features β2-microglobulin, staging of Results: The expression of miR-32 in MM patients was obviously higher than that in normal control (P <0.05). The expression of miR-32 in relapsed / refractory MM patients was obviously higher than that in newly diagnosed MM patients. The expression of miR-32 in MM patients decreased after chemical therapy than that before treatment, especially in effective group (P <0.05). There was no statistically significant change in ineffective / progress group after che The expression of miR-32 was associated to staging of MM and β2-microglobulin levels. Conclusion: Expression level of miR-32 in MM patients was significantly higher than that in normal bone marrow, these data indicated that miR-32 may play an important role in the development of MM. High-regulated expression of miR-32 was associated with β2-microglobulin and staging of MM by Durie-Salmon classification.